SCHEMBL6327779

SCHEMBL6327779

Cc1cc(CC(=O)O)c[nH]1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.48
HPGD P15428 4/20 0.45
HSD17B10 Q99714 4/20 0.45
TSHR P16473 4/20 0.45
GAA P10253 4/20 0.45
KDM4E B2RXH2 3/20 0.45
MAPT P10636 3/20 0.45
NFKB1 P19838 2/20 0.45
TDP1 Q9NUW8 2/20 0.45
LMNA P02545 2/20 0.45
RGS12 O14924 1/20 0.45
POLB P06746 1/20 0.45
APEX1 P27695 1/20 0.45
THPO P40225 1/20 0.45
BLM P54132 1/20 0.45
GNAI1 P63096 1/20 0.45
PMP22 Q01453 1/20 0.45
HIF1A Q16665 1/20 0.45
AKR1B1 P15121 1/20 0.43
ALDH1A1 P00352 5/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3415097 0.79 NPSR1 (0.48) NOTUM
SCHEMBL10621218 0.78 HSP90AB1 (0.53) NOTUMHPGDHSD17B10TSHRGAA
SCHEMBL27842774 0.77 AKR1B1 (0.41) HPGDHSD17B10TSHRGAAKDM4E
SCHEMBL16564215 0.76 GAA (0.45) HPGDHSD17B10TSHRGAAKDM4E
SCHEMBL10938196 0.74 ALDH1A1 (0.36) HPGDHSD17B10TSHRGAAKDM4E
SCHEMBL10939110 0.71 CYP26A1 (0.40) HPGDGAAKDM4EMAPTTDP1
SCHEMBL583915 0.70 AKR1B1 (0.60) HPGDHSD17B10TSHRGAAKDM4E
SCHEMBL593771 0.70 TPMT (0.48) HPGDHSD17B10TSHRGAAKDM4E
SCHEMBL1286171 0.70 AKR1B1 (0.48) HPGDHSD17B10TSHRGAAKDM4E
SCHEMBL27926108 0.69 ALDH1A1 (0.40) HPGDHSD17B10TSHRGAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6861418-B2 4-aryl substituted indolinones SUGEN, INC. (US) 2005-03-01 US disclosed
US-20040157909-A1 4-Aryl substituted indolinones SUGEN, INC. 2004-08-12 US disclosed
EP-1349852-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES Sugen, Inc. (US) 2003-10-08 EP disclosed
US-20030069297-A1 4-aryl substituted indolinones SUGEN, INC. 2003-04-10 US disclosed
WO-2002055517-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES CUI JINGRONG (US) 2002-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069297-A1 4-aryl substituted indolinones CDK5, CAMK4, TNK2 NOTUM 4561/4885HPGD 1764/4885HSD17B10 1894/4885
US-20040157909-A1 4-Aryl substituted indolinones CDK5, CAMK4, TNK2 NOTUM 4561/4885HPGD 1764/4885HSD17B10 1894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.